Advertisement

Topics

[Comment] Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions

00:20 EST 14 Nov 2017 | The Lancet

In 2006, the US Food and Drug Administration (FDA) approved trastuzumab for the treatment of patients with early-stage HER2-positive breast cancer. Clinical trials have confirmed that trastuzumab-based chemotherapy significantly reduces the risk of disease recurrence and improves survival.1,2 We know that the optimal duration of treatment is 1 year, and that trastuzumab is more efficacious when administered concomitantly with chemotherapy;3 however, efforts to further improve the outcomes of these patients with new drugs have been somewhat disappointing.

Original Article: [Comment] Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions

NEXT ARTICLE

More From BioPortfolio on "[Comment] Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...